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Bothkynurenicacidand2-acyllysophosphatidicacidhavebeenpostulatedtobetheendogenousagonistsof
GPR35. However, controversy remains whether alternative endogenous agonists exist. The molecular
targets accounted for many nongenomic actions of thyroid hormones are mostly unknown. Here we report
the agonist activity of multiple tyrosine metabolites at the GPR35. Tyrosine metabolism intermediates that
contain carboxylic acid and/or catechol functional groups were first selected. Whole cell dynamic mass
redistribution (DMR) assays enabled by label-free optical biosensor were then used to characterize their
agonist activityinnative HT-29.Molecularassays includingb-arrestin translocation,ERKphosphorylation
and receptor internalization confirmed that GPR35 functions as a receptor for
5,6-dihydroxyindole-2-carboxylic acid, 3,39,59-triiodothyronine, 3,39,5-triiodothyronine, gentisate,
rosmarinate, and 3-nitrotyrosine. These results suggest that multiple tyrosine metabolites are alternative
endogenous ligands of GPR35, and GPR35 may represent a druggable target for treating certain diseases
associated with abnormality of tyrosine metabolism.
G
-protein-coupled receptors (GPCRs) represent the largest family of cell surface receptors within the
human genome, and are historically a rich source of drug targets for small molecule modulation and
therapeutic intervention
1,2. Orphan GPCRs whose natural ligands and functions are unknown represent
potential new targets for drug discovery
3. Identification of native ligands for these receptors is crucial to under-
stand their physiological and pathophysiological functions. GPR35 was first identified to be a class A orphan
GPCR consisting of 309 amino acids
4. GPR35b, a splicing variant that contains an N-terminal extension of 31
aminoacids,waslaterdiscoveredingastriccancercells
5.GPR35isexpressedinvarioustissuesincludingstomach,
gastrointestinal tissues, and several types of immune cells
6. Up-regulation of GPR35 has been found in human
mast cells upon stimulation with IgE antibodies
7, human macrophages treated with the environmental contam-
inant polycyclic aromatic hydrocarbon benzo[a]pyrene
8, failing heart cells
9, and gastric cancer cells
5. Further,
deletion of GPR35 gene may, at least partly, be responsible for phenotypic resemblance to Albright hereditary
osteodystrophy, as well as for brachydactyly mental retardation syndrome
10.
Kynurenicacid,atryptophanmetaboliteofthekynureninepathway,hasbeenpostulatedtobeanaturalagonist
of GPR35
11. However, controversy remains as to whether it reaches sufficient tissue concentrations to be the
endogenous ligand
6. 2-Acyl lysophosphatidic acid (2-acyl-LPA) was recently proposed as an alternative natural
agonistofGPR35
12.However,itstillremainstobeprovenwhere2-acyl-LPAistheendogenousagonistofGPR35,
giventhat itisdifficult to separate itsactionviaGPR35fromthose viaother endogenous LPAreceptors, multiple
ofwhichareoftenco-expressedinnativecells
13.Here,wesetouttodeterminepotentialGPR35agonistactivityof
tyrosinemetabolitesusingdynamicmassredistribution(DMR)assayinconjunctionwithTangob-arrestinassay.
This work was motivated by (1) our recent discovery that certain tyrosine derivatives, tyrphostins including
tyrphostin-51 and tyrphostin-25, are potent GPR35 agonists
14; (2) the fact that many of tyrosine metabolites
including catecholamines have been long recognized to be native ligands of several families of GPCRs
15; and (3)
the unknown molecular targets accounting for many nongenomic actions of thyroid hormones
16. We were
primarily focused on carboxylic acid- and/or catechol-containing tyrosine metabolism intermediates, based on
our recent structure activity relationship analysis of several classes of novel GPR35 agonists
14,17. DMR assays
enabled by label-free optical biosensor are pathway-unbiased yet pathway-sensitive, permitting detecting the
agonist activity of ligands with wide pathway coverage and high sensitivity
18–21. The GPR35 Tango assay directly
probes the agonist activity of ligands at the GPR35 by measuring alteration in gene expression directly linked to
the GPR35 activation-mediated b-arrestin translocation
14,17. We found that GPR35 functions as a receptor for
several metabolites in tyrosine metabolism pathway including gentisate, 5,6-dihydroxyindole-2-carboxylic acid
(DHICA), 3,39,59-triiodothyronine (reverse T3), 3,39,5-triiodothyronine (T3), dihydrocaffeic acid and rosmar-
inate. 3-Nitrotyrosine, a product of tyrosine nitration, was also found to be a GPR35 agonist.
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Pharmacological characterization of know GPR35 agonists. We
first characterized in detail the pharmacology of known GPR35
agonists including cromolyn disodium
7, kynurenic acid
11, zap-
rinast
22, pamoic acid
23, and niflumic acid
24, as well as known
GPR35 antagonist SPB05142
23. DMR agonist profiling using HT-
29 cells showed that all known GPR35 agonists triggered a robust
DMR signal in adose dependent manner. At the saturating doses, all
agonistsledtoaDMRsharingsimilarcharacteristics,suggestingthat
they activate the same target, GPR35. The dose response of zaprinast
in HT-29 cells was showed in Fig. 1a. Conversely, SPB05142 up to
1 mM led to little or no DMR signal in HT-29 cells (Fig. 1b). The
non-linear regression analysis, based on the maximal amplitude, led
to a potency rank order of pamoic acid (EC50, 2.1 nM) . zaprinast
(0.14 mM) . cromolyn disodium (0.52 mM) . niflumic acid
(1.11 mM) ? kynurenic acid (152 mM) (Fig. 1c, Table 1). The
efficacy to trigger DMR was similar, but not identical, for these
agonists, suggesting that these agonists were divergent in their
functional selectivity.
Pharmacological profiling using Tango assays in U2OS-GPR35-
bla cell line gave rise to almost identical potency rank order: pamoic
acid (2.69 mM) . zaprinast (6.12 mM) . cromolyn disodium
(9.67 mM) . niflumic acid (41.6 mM) ? kynurenic acid (.
500 mM)(Fig.1d).Theefficacy,basedonthemaximalresponseafter
normalized to the maximal response of zaprinast within the same
plate, was found to be pamoic acid (108%) , zaprinast (100%) ,
cromolyn disodium (97%) . kynurenic acid (.60%) . niflumic
acid (39%). As expected, SPB05142 was inactive in Tango assays.
Furthermore, SPB05142 was found to dose-dependently inhibit
the DMR arising from 10 nM pamoic acid, 500 nM zaprinast, 2 mM
cromolyn disodium, 8 mM niflumic acid, or 0.5 mM kynurenic
acid, leading to an apparent IC50 of 3.9760.24 mM, 10.460.9 mM,
13.561.6 mM, 13.261.4 mM, and 4.4160.47 mM (2 independent
measurements, n 5 4), respectively (Table 1). Collectively, these
results suggest that these ligands are indeed GPR35 agonists, and
their pharmacological profiles obtained are in line with what
reported in literature.
Gentisate, an intermediate of tyrosine degradation pathway, is a
GPR35 agonist. Phenylalanine is an essential amino acid and the
precursor of tyrosine. Both amino acids share a common pathway of
degradation which occurs in liver and ultimately leads to fumarate
andacetoacetate,accountingfortheglycogenicandketogenicnature
of both amino acids, respectively
25 (Fig. 2a). Since HT-29 was
previously showed to endogenously express GPR35 at relatively
high level
14,17, we first examined the DMR signals of several
molecules in this pathway in HT-29 using DMR assays. Results
showed that at 1 mM only gentisate resulted in a robust DMR
signal, while homogentisate led to a much smaller DMR, and other
moleculesincludingL-phenylalanine,DL-phenylalanine,L-tyrosine,
DL-tyrosine, 4-hydroxy-phenylpyruvate, 2-hydroxy-3-(4-hydroxy-
phenyl)propenoate, and fumarate were inactive (Fig. 2b, Table 1).
Figure 1 | Pharmacological characterization of known GPR35 agonists. (a) Real time DMR dose response of zaprinast. (b) Real time DMR dose
responseofSPB05142.(c)TheDMRamplitudesofknownGPR35ligandsasafunctionoftheirdoses.(d)TheTangoresponses ofknownGPR35ligands
as a function of their doses. The Tango responses were normalized to the maximal response of zaprinast within the same plate. Except for zaprinast (8
independentmeasurements,eachinduplicate,n516),allotherdatarepresentsmean6s.d.from2independentmeasurements,eachinduplicate(n54).
www.nature.com/scientificreports
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exhibited characteristics almost identical to those of several known
GPR35 agonists including zaprinast, kynurenic acid and tyrphostin-
51 reported recently
14. Nonlinear regression analysis revealed that
gentisate gave rise to a monophasic dose response, which was best
fitted by a single-phase sigmoidal curve, leading to a single EC50 of
69.667.1 mM (2 independent measurements, n54) (Fig. 2d). The
maximal DMR amplitude induced by gentisate at saturating doses
was comparable to those of known GPR35 full agonists including
zaprinastandtyrphostin-51
14,butwasgreaterthanthatofkynurenic
acid (Table 1). Furthermore, gentisate at high doses also resulted
in detectable FRET signal arising from b-arrestin translocation
via GPR35 in the engineered U2OS-GPR35-bla cells (Fig. 2e).
Together, these results suggest that gentisate is a GPR35 agonist.
DHICA, an intermediate of melanin biosynthesis pathway, is a
GPR35 agonist. Eumelanin is a common type of melanin pigment,
which is synthesized from tyrosine in vivo through three chro-
mophoric phases, the red pigment L-dopachrome, the purple
intermediate melanochrome, and the broad absorption eumela-
nin
26. L-dopachrome is converted into 5,6-dihydroxyindole via a
spontaneous decarboxylation and into DHICA via an enzymatic
tautomerization (Fig. 3a). We examined the ability of both L-
DOPA and DHICA to trigger DMR signals in HT-29. Results
showed that L-DOPA led to a dose-dependent DMR, but did not
reach a saturated level up to 1 mM (Fig. 3b). In contrast, DHICA
resulted in a clear dose-dependent and saturable DMR (Fig. 3c).
Interestingly, the DMR of DHICA at saturating doses was distinct
fromthoseinducedbygentisate,characterizedbythelackoftheearly
peak ofthegentisate DMR.Nonlinearregressionanalysis ofthedose
response of DHICA, based on the DMR amplitudes at 50 min
poststimulation, yielded a single EC50 of 24.262.7 mM (2 in-
dependent measurements, n54) (Fig. 3d). Furthermore, DHICA
also resulted in robust FRET signal arising from b-arrestin trans-
location in U2OS-GPR35-bla cells (Fig. 3e). The dose response of
DHICA obtained using Tango assay was biphasic – at the low dose
range the DHICA response was saturable, yielding an EC50 of
22.961.6 mM and a maximum of 75% of the zaprinast response (2
independent measurement, n 54); but at the two highest doses the
FRET signal started to decrease. In contrast, L-DOPA up to 1 mM
was inactive in Tango assays. Together, these results suggest that
DHICA was a moderately potent GPR35 agonist.
Dihydrocaffeic acid, rosmarinate, and DHPG, intermediates
of catecholamine degradation pathways, are GPR35 agonists.
Catecholamines are catabolized to a series of metabolites through
the sequential actions of catecholamine-O-methyltransferase and
monoamine oxidase. Since several intermediates in catecholamine
degradation pathways contain carboxylic acid and/or catechol
groups (Fig. 4a), we were interested in the potential agonist
activity of these intermediates at the GPR35. DMR agonism
profiling showed that four metabolites including dihydrocaffeic
Table 1 | Compounds and their pharmacological characteristics. The EC50 was obtained using DMR agonism and Tango assays, while the
antagonistIC50wasforSPB05142toblocktheDMRofeachagonistatitsEC80,andtheirefficacywasthemaximalresponsesofeachligand
measured using DMR and Tango assays*
Compound
EC50 (mM) IC50 (mM)** Efficacy
DMR Tango Antagonist DMR (pm) Tango (% Zaprinast)
Zaprinast 0.1460.01 6.1260.51 10.460.9 250617 100
Pamoic acid 0.002160.0002 2.6960.21 3.9760.24 222614 108
Niflumic acid 1.1160.09 41.663.9 13.261.4 223611 39
Cromolyn disodium 0.5260.04 9.6760.71 13.561.6 252616 97
Kynurenic acid 152617 .500 4.4160.47 203613 .60
Homogentisate .500 Inactive No inhibition Off-target
Gentisate 69.667.1 .500 6.6560.49 309619 .20
L-DOPA .500 Inactive 7.4660.54 Off-target
DHICA 24.262.7 22.961.6 9.1760.70 310611 75
Dihydrocaffeic acid 342641 186621 3.9260.31 293612 46
Rosmarinate 29.462.7 169617 2.2260.19 320611 63
DOPAC .500 10667 4.6060.31 .200 44
DHPG 239637 563667 1.9760.15 310612 18
3-Iodo-L-tyrosine .500 Inactive 3.6260.0.27 .50
3,5-Diiodo-L-tyrosine 304645 Inactive 2.7860.19 254619
T3 5065 513661 3.2560.21 205615 40
Reverse T3 5.8960.39 10869 2.8460.23 276612 108
L-Thyroxine (T4) .500 .500 2.0760.17 .100 .20
3-Nitro-L-tyrosine 142627 .500 6.7460.39 330613 .20
L-Tyrosine Inactive Inactive
DL-Tyrosine Inactive Inactive
L-Phenylalanine Inactive Inactive
DL-Phenylalanine Inactive Inactive
4-hydroxy-pheylpyruvate Inactive Inactive
a-methyl-L-DOPA Inactive Inactive
4-Hydroxyphenylacetate Inactive Inactive
Homovanillic acid Inactive Inactive
Ethyl homovanillate Inactive
3-Methoxytyramine Inactive Inactive
Sodium fumarate Inactive Inactive
*The data represents mean6s.d. from 2 independent measurements (n54).
**TheIC50wasobtainedforeachagonistatafixeddose:10 nMpamoicacid,500 nMzaprinast,2 mMcromolyndisodium,8 mMniflumicacid,0.5 mMkynurenicacid,0.5 mMgentisate,1 mML-DOPA,
64 mM DHICA, 0.5 mM dihydrocaffeic acid, 32 mM rosmarinate, 1 mM DOPAC, 1 mM DHPG, 1 mM 3-iodo-L-tyrosine, 1 mM 3,5-diiodotyrosine, 16 mM rT3, 50 mM T3, 1 mM T4, and 0.5 mM
3-nitro-L-tyrosine.
www.nature.com/scientificreports
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(Fig. 4b to e, respectively), but a-methyl-L-DOPA, homovanillic
acid, ethyl homovanillate, and 3-methoxytyramine were inactive
(Table 1). The DMR signals of the four DMR-active metabolites
were similar to that of DHICA. Except for DOPAC which up to
1 mM did not saturate its DMR signal, the DMR response was sa-
turabletotheincreasingdosesofdihydrocaffeicacid,rosmarinate,or
DHPG, leading to an EC50 of 342641 mM, 29.462.7 mM, and
239637 mM (2 independent measurements, n54), respectively
(Fig. 4f). Furthermore, the four DMR-active metabolites were also
able to trigger b-arrestin translocation in U2OS-GPR35-bla cells, with
an EC50 of 186621 mM, 169617 mM, 10667 mM, and 563667 mM
(2 independent measurements, n54) for dihydrocaffeic acid, rosmari-
nate, DOPAC and DHPG, respectively (Fig. 4g). The efficacy was
found to be in the order of rosmarinate . dihydrocaffeic acid ,
DOPAC . DHPG (Table 1). Together, these results suggest that
these four DMR-active metabolites are GPR35 agonists.
Both T3 and reverse T3, intermediates of thyroid hormone
synthesis pathway, are GPR35 agonists. Thyroid hormones
including T4 and T3 are tyrosine-derived hormones produced by
follicular cells of the thyroid gland and are primarily responsible
for regulation of metabolism, growth and development
27.A sa
storage hormone and the most abundant, T4 is produced through
enzymatic cleavage of the precursor thyroglobulin. Appropriately
40% of T4 is converted to the most active hormone T3, and the
remaining 60% of T4 goes to the inactive reverse T3 (Fig. 5a).
DMR agonism profiling showed that all five thyroid-related
molecules tested were able to trigger DMR in HT-29 cells. 3-Iodo-
L-tyrosine at the highest dose examined (1 mM) led to a small but
Figure 2 | Gentisate, a tyrosine degradation metabolite, is a GPR35 agonist. (a) Scheme showing the tyrosine degradation pathway. (b) The DMR
signalsofseveralmetabolites, eachat1 mM,inHT-29cells.(c)Realtime DMRdoseresponsesofgentisateinHT-29.(d)ThemaximalDMRamplitudes
of different molecules as a function of their doses. (e) The b-arrestin translocation dose responses of different molecules. All data represents mean6s.d.
from 2 independent measurements, each in duplicate (n54).
www.nature.com/scientificreports
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allledtoacleardose-dependentDMR(Fig.5ctoe),andT4appeared
to be less potent (Fig. 5f). The DMR of 3,5-diiodo-L-tyrosine, T3 or
reverse T3 at its respective saturating doses exhibited characteristics
that are intermediate between gentisate and DHICA. The potency
rank ordertotrigger DMRin HT-29cells wasfoundto bereverse T3
(EC50, 5.8960.39 mM) . T3 (5065 mM) . 3,5-diiodo-L-tyrosine
(304645 mM) (2 independent measurements, n54) (Fig. 5g).
Similarly, except for 3-iodo-L-tyrosine, all other four thyroid mole-
cules were found to be active in causing b-arrestin translocation in
U2OS-GPR35-bla cells (Fig. 5h). Remarkably, reverse T3 acted as a
full agonist similar to zaprinast, while T3 was a partial agonist to
resultinb-arrestintranslocation. Together, theseresultssuggest that
both reverse T3 and T3 are GPR35 agonists.
Nitrotyrosine,aproductoftyrosinenitration,isaGPR35agonist.
Nitrotyrosine is a product of tyrosine nitration mediated by reactive
nitrogen species including peroxynitrite anion and nitrogen dioxide,
and is considered a biomarker of NO-dependent, reactive nitrogen
species-induced nitrative stress
28. DMR agonism profiling showed
that 3-nitrotyrosine triggered a robust DMR signal in HT-29 cells,
whose characteristics were almost identical to gentistate (Fig. 6a).
Nonlinear regression analysis of the monophasic dose response of 3-
nitro-L-tyrosine showed that it exhibited a relatively low potency
with an EC50 of 142627 mM (2 independent measurements, n54)
(Fig.6b).Tangoassaysconfirmedthat3-nitro-L-tyrosinewasableto
result in b-arrestin translocation in U2OS-GPR35-bla cells (Fig. 6c).
Together, these results suggest that 3-nitro-L-tyrosine is a GPR35
agonist.
Figure 3 | DHICA, an intermediate of melanin biosynthesis pathway, is a GPR35 agonist. (a) Scheme showing the melanin biosynthesis pathway. (b)
Real time DMR dose responses of L-DOPA. (c) Real time DMR dose responses of DHICA. (d) The maximal DMR amplitudes of both molecules as a
function of their doses. (e) The b-arrestin translocation dose responses of both molecules. All data represents mean6s.d. from 2 independent
measurements, each in duplicate (n54).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 373 | DOI: 10.1038/srep00373 5Figure 4 | Dihydrocaffeic acid, rosmarinate, DOPAC, and DHPG, four intermediates of L-DOPA and catecholamine degradation pathways, are
GPR35 agonists. (a) Scheme showing L-DOPA and catecholamine degradation pathway. (b to e) Real time DMR dose responses of dihydrocaffeic acid
(b),rosmarinate(c),DOPAC(d)andDHPG(e).(f)ThemaximalDMRamplitudesofdifferentmoleculesasafunctionoftheirdoses.(g)Theb-arrestin
translocation dose responses of different molecules. All data represents mean6s.d. from 2 independent measurements, each in duplicate (n54).
www.nature.com/scientificreports
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many compounds may exhibit polypharmacology and DMR mea-
surement is integrative in nature, a compound-induced DMR may
contain contributions from multiple targets/pathways which the
compound activates
19. Thus, we examined the specificity of the
DMR signals of the twelve DMR-active compounds to the ac-
tivation of GPR35 using DMR antagonist assays. Each com-
pound was assayed at a dose close to its respective EC50 to EC80
in the presence of SPB05142. Results showed that except for
DOPA whose DMR was partially inhibited, SPB05142 dose-
dependently inhibited the DMR arising from all other eleven
agonists in HT-29 cells, resulting in similar potency (Fig. 7,
Table 1). It is worthy noting that for gentisate, dihydrocaffeic
acid, rosmarinic acid, DOPAC and DHPG, there were residual
DMR signal in the presence of 64 mM SPB05142. Nonetheless,
these results suggest that the DMR of L-DOPA is partially due
to the activation of GPR35, and the DMR of all other ligands
are mostly specific to the activation of GPR35.
Representative GPR35 agonists result in receptor internalization
and ERK phosphorylation. Since GPR35 activation is known to
cause receptor internalization, we further investigated represen-
tative ligands. Results showed that under unstimulated conditions
GPR35 was primarily located at the cell surface (Fig. 8a). Stimu-
lation of HT-29 with 50 mM gentisate, 2 mM L-DOPA, 50 mM
DHICA, 500 mM DOPAC, 5 mM reverse T3, 200 mM T4, or
50 mM 3-nitrotyrosine all led to obvious internalization of GPR35
(Fig. 8b to h).
Since ERK phosphorylation is a hallmark of the activation and
signaling of many GPCRs including GPR35
14,17,23, we examined
the ability of representative ligands to result in ERK phosphoryla-
tion. Results showed that stimulation of HT-29 cells with all
Figure 5 | Thyroid molecules are GPR35 agonists. (a) Scheme showing thyroid hormone biosynthesis pathway. (b to e) Real time DMR dose responses
of 3-iodo-L-tyrosine (b), 3,5-diiodo-L-tyrosine (c), T3 (d), reverse T3 (e), and T4 (f). (g) The maximal DMR amplitudes of different molecules as a
function of their doses. (h) The b-arrestin translocation dose responses of different molecules. All data represents mean6s.d. from 2 independent
measurements, each in duplicate (n54).
www.nature.com/scientificreports
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Together, these results suggest that these tyrosine metabolites
are GPR35 agonists.
Discussions
Three lines of evidence suggest the presence of alternative endogen-
ous agonists for GPR35. First, we have found that certain tyrosine
derivatives, tyrphostins including tyrphostin-51, tyrphostin-23, and
tyrphostin-47, are GPR35 agonists with high to moderate potency
14.
Tyrphostins are a family of tyrosine analog compounds, and were
originally synthesized as inhibitors of tyrosine kinases
29. Second,
Wang et al.
11 found that the tryptophan metabolite kynurenic acid
is an agonist of GPR35, but controversy remains as to whether it is
the endogenous ligand
6. We had showed that kynurenic acid was
indeed able to result in DMR in HT-29, and to trigger b-arrestin
translocation in U2OS-GPR35-bla cells, but with quite low potency;
its EC50 was 152 mM and .500 mM, respectively (Table 1)
14. Third,
tyrosine is metabolized to a diverse array of molecules, many of
which are natural agonists for distinct families of receptors.
Catecholamines are a family of neurotransmitters including dopa-
mine, norepinephrine and epinephrine. Dopamine is synthesized in
neurons and the medulla of the adrenal glands, and is the natural
agonist for the five dopamine receptors. Norepinephrine and epi-
nephrine are synthesized in the sympathetic neurons affecting the
heart,andarethenaturalagonistsforadrenergicreceptorsconsisting
of nine members. L-DOPA, an intermediate in both catecholamines
andmelaninbiosynthesis pathways,wasrecentlydiscoveredtobean
agonist of GPR143
30. Succinate, a product of amino acid catabolism
pathway, was found to be an agonist for GPR91
31. Last but not least,
thyroid hormones have been long recognized to be potent agonists
for thyroid hormone receptors, a family of four nuclear receptors
27.
Rapid and nongenomic actions of the thyroid hormone T4 have also
been discovered
16, and are believed to mediate, at least partly,
through a receptor on the integrin avb3
32.
DMR assay enabled by label-free resonant waveguide grating bio-
sensorsisphenotypicinnature,andpermitsdiscoveryofmany,ifnot
all, modes of action of ligand molecules for a receptor
19,21,33. Using
DMR profiling, we found that several tyrosine metabolites including
gentisate, DHICA, dihydrocaffeic acid, rosmarinate, DHPG, 3,5-
diiodo-L-tyrosine, T3 and reverse T3 are GPR35 agonists but with
distinct efficacy and potency. Free 3-nitrotyrosine was also a GPR35
agonist. The potency rank order was reverse T3 (EC50, 5.89 mM) .
DHICA (24.2 mM) , rosmarinate (29.4 mM) . T3 (50 mM) . gen-
tisate (69.6 mM) . 3-nitro-L-tyrosine (142 mM) . DHPG
(239 mM). 3,5-diiodo-L-tyrosine (304 mM) , dihydrocaffeic acid
(342 mM); and among them reverse T3 was the most potent GPR35
agonisttoresultinDMRinHT-29cells.Tangoassaysconfirmedthat
all, but 3,5-diiodo-L-tyrosine, of these DMR-active molecules were
activetotriggerb-arrestintranslocationviaGPR35intheengineered
cellline;andDHICAwasthemostpotentagonist,andreverseT3the
second.Interestingly,reverseT3exhibitedthehighestefficacy,which
is comparable to zaprinast.
DHICA and 5,6-dihydroxyindole are two key monomer building
blocks of eumelamins, the black to brown pigments found in human
skin, hair and eyes. The plasma concentration of DHICA was
unknowntous;however,itsO-methyderivative,6-hydroxy-5-meth-
oxyindole-2-carboxylic acid, was found to be 0.51 ng/ml in healthy
patients, and can be up to 4.09 ng/ml in patients having melanoma
metastases
34.TheDHICAlevelisoftenincreaseduponUVexposure.
Considering that local concentration of DHICA may be much
higher, the GPR35 agonist activity of DHICA is worthy of further
attention and may be of biological relevance.
L-DOPA, the precursor of DHICA, has been shown to have a
regulatory role in melanogenesis and other cellular functions
35.
GPR143 was recently proposed to be a membrane receptor target
for L-DOPA
30. L-DOPA was found to have a weak agonist activity
at the GPR35, beside the activation of another target in HT-29.
Previous cross-linking experiments of cells cultured in low tyrosine
media have revealed that L-DOPA binds specifically to a 30 kDa cell
surface protein (a molecular weight, M.W., identical to GPR35),
besides a 55 kDa cell surface protein (a M.W. close to GPR143)
36.
The DMR of L-DOPA in HT-29 may be due to the co-activation of
both GPR143 and GPR35. The expression and function of GPR143
in HT-29 was currently under investigation.
Gentisate is an intermediate of tyrosine catabolism pathway, lead-
ingtotheproduction of fumarate andpyruvate.Both eukaryotic and
prokaryotic organisms catabolize phenylalanine and tyrosine by a
commonperipheralpathwaywhichresultsinhomogentisate,acent-
ral intermediate prior to gentisate
37. Gentisate is also an active oxy-
metabolite of aspirin, resulting in analgesic and anti-inflammatory
effects
38. Although the plasma concentration of endogenous genti-
sate was unknown to us, it has been detected for gentisate to reach a
concentration up to 15 mM in plasma and synovial fluid of patients
receivingaspirintherapyforrheumatoidarthritis
39.Sincegentisateis
more likely to be formed by disease processes where activated cells
produce oxyradicals
38, its local concentration at inflammation sites
during similar aspirin therapy could be much higher for febrile
patients than healthy individuals. Therefore, we hypothesized that
themoderatepotencyofgentisatetoactivateGPR35mayberelevant
to the clinical effects of aspirin.
Figure 6 | 3-Nitro-L-tyrosine,aproductoftyrosinenitration,isaGPR35agonist. (a)RealtimeDMRdoseresponsesof3-nitrotyrosineanditsstructure.
(b) The maximal DMR amplitudes of 3-nitrotyosineas a function of its doses. (c) The b-arrestin translocation dose response of 3-nitrotyrosine. All data
represents mean6s.d. from 2 independent measurements, each in duplicate (n54).
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DOPA degradation pathway. Rosmarinic acid is also believed to be
an active constituent of Danshen, the dried root of Salvia miltior-
rhiza, which is a commonly used traditional Chinese medicine for
the treatment of cardiovascular and cerebrovascular diseases
40,41.
Here we found that rosmarinic acid exhibited much higher
potency to activate GPR35 than dihydrocaffeic acid did. The ago-
nist activity at the GPR35 of rosmarinic acid may be relevant to
its clinical feature, since it share such a molecular mode of action
with furosemide. Furosemide, a clinically used loop diuretic to
Figure 7 | The DMR characteristics and specificity to GPR35 activation of different ligands. (a to l) The DMR signal of each ligand in the absence and
presence of 64 mM SPB05142: (a) gentisate, (b) L-DOPA, (c) DHICA, (d) dihydrocaffeic acid, (e) rosmarinic acid, (f) DHPG, (g) 3-iodo-L-tyrosine, (h)
3,5-diiodo-L-tyrosine, (i) reverse T3, (j) T3, (k) T4, and (l) 3-nitro-L-tyrosine. The concentration of each agonist was indicated in the graph. All data
represents mean6s.d. from 2 independent measurements, each in 8 replicates (n516).
www.nature.com/scientificreports
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be a GPR35 agonist
42.
Thyroid hormone biosynthesis metabolites including T3, reverse
T3, 3,5-diiodo-L-tyrosine and T4 were also found to be GPR35 ago-
nists. T4, once produced by the thyroid gland, lasts for weeks in the
bodyandisconvertedtoT3andreverseT3.ReverseT3isconsidered
to be not bio-active and can block the actions of T3 at thyroid recep-
tors when produced in excess. Various nongenomic actions of
thyroid hormones have been long reported to be originated from
cytoplasmic proteins or the cell surface integrin receptor avb3.
16
Further, much attention was focused on the nongenomic action of
both T4 and T3 at a concentration range being close to their physio-
logical free levels of the hormone
16. Compared to the nongenomic
actions reported in literature, these iodothyronines exhibited much
lowerpotency asGPR35agonists. However,considering theincreas-
ing production of reverse T3 in thyroid disorders
43–47 as well as the
up-regulation of GPR35 in certain diseases
5,7–9, the GPR35 agonist
activity of thyroid hormones may be of biological relevance, and
represent a novel molecular mode of action contributing to the
increasing list of nongenomic actions of thyroid hormones.
The two metabolites including DOPAC and DHPG in the cate-
cholamine degradation pathways were also found to exhibit agonist
activity at the GPR35. Catecholamines are biosynthesized in both
neuronal and non-neuronal cells, including the central nervous
system, sympathetic nerves, adrenal medulla, gastrointestinal tract,
and kidneys. Dopamine is preferentially converted to acid metabo-
lites including DOPAC, and noradrenaline and adrenaline are pref-
erentially converted to alcohol metabolites including DHPG
48. The
plasma concentration of DHPG was reported to be about 5 nM in
healthy patients
49. Thus, DHPG alone may not represent an endo-
genous ligand of GPR35.
3-Nitrotyrosine is a derivative of tyrosine during nitrative stress.
Amassing evidence suggest that several nitrating species including
nitrogen dioxide, peroxynitrite and nitrous acid can be produced
during inflammation
28. Free 3-nitrotyrosine can be detected in
human plasma and other biofluids and is generally considered a
biomarkerofnitrativestress
50.Theconcentrationofendogenousfree
3-nitrotyrosine in the plasma is ,100 nM under normal physio-
logicalconditions
51,52,butcanincreaseby,100foldinthejointfluid
of rheumatoid arthritis
53and up to 100 mM in the plasma of patients
with septic shock and renal failure
54. Given that the local concentra-
tion of free 3-nitrotyrosine in close proximity to the site of produc-
tion of nitrating species can be much higher, the agonist activity at
the GPR35 of 3-nitrotyrosine may be of biological relevance.
In summary, our study showed that GPR35 is a target of multiple
tyrosine metabolites including DHICA, reverse T3, T3, rosmarinate,
as well as a product of tyrosine nitration 3-nitrotyrosine. Since each
of these metabolites does not reach sufficient plasma concentration
Figure 8 | GPR35 agonists trigger receptor internalization in HT-29 cells. Representative confocal fluorescence images of HT-29 under different
conditions:(a)treatedwiththeassayvehiclecontaining0.1%DMSO;(btoh)treatedwithvariousligandsatafixeddose:(b)50 mMgentisate,(c)2 mM
L-DOPA,(d)50 mMDHICA,(e)0.5 mMDOPAC,(f)5 mMreverseT3(rT3),(g)200 mMT4,and(h)50 mM3-nitrotyrosine.Theimageswereobtained
aftercompoundtreatmentfor1 hr,permeabilized,stainedwithanti-GPR35,followedbyfluorescentsecondaryantibody.Red:GPR35stains;Blue:nuclei
stains with DAPI. Representative images obtained from 2 independent measurements were used.
Figure 9 | GPR35 agonists result in robust ERK phosphorylation. ERK phosphorylation induced by representative ligands, each at different doses. The
phosphorylated ERK and total ERK were plotted, and actin the control. Before cell lysis, the cells were treated with respective drugs for 30 min.
Representative images were obtained from 2 independent measurements.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 373 | DOI: 10.1038/srep00373 10tofullyactivateGPR35onitsown,our discoverythatmultiple meta-
bolites having agonist activity at the GPR35 are enriched within
tyrosine metabolism pathway may point to a possibility that some,
ifnotall,ofthesemetabolitesworkcollectivelytoregulatethephysio-
logical and pathophysiological function of GPR35.
Methods
CompoundsandReagents.Kynurenicacid,homogentisate,gentisate,L-DOPA(3,4-
dihydroxy-L-phenylalanine), DOPAC (3,4-Dihydroxyphenylacetic acid), DHPG
(3,4-dihydroxyphenylglycol), 3-iodo-L-tyrosine, 3,5-diiodo-L-tyrosine, reverse T3,
T3, T4 (L-thyroxine), 3-nitro-L-tyrosine, L-tyrosine, DL-tyrosine, L-phenylalanine,
DL-phenylalanine, a-methyl-L-DOPA, 4-hydroxyphenylacetate, homovanillic acid,
ethyl homovanillate, 3-methoxytyramine, sodium fumarate, and rosmarinate were
obtained from Sigma Chemical Co. (St. Louis, MO). Dihydrocaffeic acid (3-(3,4-
dihydroxyphenyl)propionicacid) wasobtainedfrom Frontier Scientific Services, Inc.
(Newark, DE). 4-Hydroxy-pheylpyruvate was obtained from UkrOrgSynthesis, Ltd.
(Ukraine). Zaprinast was obtained from Tocris Chemical Co. (St. Louis, MO).
SPB05142 (CID2745687; methyl-5-[(tert-butylcarbamothioylhydrazinylidene)-
methyl]-1-(2,4-difluorophenyl)-pyrazole-4-carboxylate) was obtained from Ryan
Scientific, Inc. (Mt. Pleasant, SC). EpicH 384-well biosensor microplates were
obtained from Corning Inc. (Corning, NY, USA).
Synthesis and characterization of DHICA. DHICA was custom synthesized by
BioDuro Corp. (Beijing, China). Briefly, to a solution of 2-bromo-4,5-
dimethoxybenzaldehyde (2.45 g, 10 mmol) in dimethyl sulfoxide (DMSO, 40 mL)
was added CuI (200 mg, 1 mmol) and Cs2CO3 (6.52 g, 20 mmol) under N2. After
stirring for 10 minutes, ethyl 2-isocyanoacetate (1.25 g, 11 mmol) was added
dropwise and stirring continued for 16 hours at 80uC. The reaction was quenched
with water (200 mL) and extracted with 80 mL ethyl acetate (EtOAc) three times.
After removal of the solvent, the residue was purified by flash column
chromatography on silica gel (petroleum ether/EtOAc 55:1) to give ethyl 5,6-
dimethoxy-1H-indole-2-carboxylate (1.5 g, 60% yield) as off-white solid.
1H NMR
(300 MHz,CDCl3):dppm8.75(s,1H),7.12(s,1H),7.04(s,1H),6.85(s,1H),4.39(q,
2H), 3.92 (m, 6H), 1.41 (t, 3H). Next, to the solution of ethyl 5,6-dimethoxy-1H-
indole-2-carboxylate (120 mg, 0.48 mmol) in EtOH/H2O(5 mL/5 mL) was added
NaOH (77 mg, 1.92 mmol). The mixture was stirred for 16 hours at room
temperature. After removal of the solvent, the residue was adjusted to pH 2,3 and
filtered, the filter cake was dried to give 5,6-dimethoxy-1H-indole-2-carboxylic acid
(80 mg, 75% yield) as off-white solid. Lastly, to the solution of 5,6-dimethoxy-1H-
indole-2-carboxylic acid (80 mg, 0.36 mmol) in dichloromethane (DCM, 10 mL)
wasaddedBBr3(0.1 mL,1.08 mmol)dropwiseat278uC.Themixturewasstirredfor
6 hours at room temperature. The mixture was quenched with water (5 mL) and
filtered, the filter cake was washed by water and DCM to give DHICA (30 mg, 43%
yield) as off-white solid.
1H NMR (300 MHz, DMSO-d6) d ppm: 12.41 (s, 1H), 11.11
(s,1H),8.07(s,1H),8.56(s,1H),6.87(m,3H);LCMS(m/z):ES-192(M–H).DHICA
with a purity of .95% received from the CRO was used directly.
Cell Culture. Human colorectal adenocarcinoma HT-29 was obtained from
American Type Cell Culture (Manassas, VA, USA). The cells were cultured in
McCoy’s 5a Medium Modified supplemented with 10% fetal bovine serum, 4.5g/liter
glucose,2 mMglutamine,andantibioticsat37uCunderair/5%CO2.Tango
TMU2OS-
GPR35-blacells were purchased from Invitrogen, and were cultured according tothe
protocols recommended by the supplier. Briefly, the cells were passed using McCoy’s
5A medium (Invitrogen 16600–082) supplemented with 10% dialyzed fetal bovine
serum, 0.1 mM NEAA, 25 mM Hepes (pH 7.3), 1 mM sodium pyruvate, 100 U/ml
penicillin, 100 mg/ml streptomycin, 200 mg/ml zeocin, 50 mg/ml hygromycin, and
100 mg/ml geneticin in a humidified 37uC/5% CO2 incubator.
Dynamic mass redistribution assay. EpicH system (Corning Inc., Corning, NY), a
wavelength interrogation reader system based on resonant waveguide grating
biosensors in microtiter plates, was used for dynamic mass redistribution (DMR)
assays
20. The Epic system consists of a temperature-control unit (26uC), an optical
detectionunit,andanon-boardliquidhandlingunitwithrobotics.Thedetectionunit
is centered on integrated fiber optics, and enables kinetic measures of cellular
responses with a time interval of ,15 sec. For whole cell DMR assays, cells were
directly seeded in EpicH plates and cultured overnight to form confluent monolayer
in the cell culture medium; and the cells were then washed twice using plate washer,
and maintained with Hank’s balanced salt solution (1x HBSS) and further incubated
inside the system for 1 hr before measurements.
For DMR agonism profiling, a 2-min baseline was first established. Immediately
after the compound addition using the onboard liquid handler, the cellular responses
were recorded in real time for about 1 hr. For DMR antagonist assays, cells were
initiallytreated withaGPR35antagonistfor1 hr.Thebaselinewasestablished, anda
testingagonistatafixeddosewasaddedandthecellularresponseswerethenrecorded
in real time. All EC50 or IC50 described in the main text were calculated based on the
maximal amplitudes of DMR signals within 1 hr poststimulation. Cellular responses
induced by the assay buffer with 0.1% dimethyl sulfoxide (DMSO) were used as
negative controls. All DMR signals were background corrected.
Tango b-arrestin translocation gene reporter assays. The U2OS-GPR35-bla cell
line stably expresses two fusion proteins: human GPR35 linked to a Gal4-VP16
transcription factor through a TEVprotease site,and b-arrestin/TEV protease fusion
protein. The cell line also stably expresses the b-lactamase reporter gene under the
control of a UAS response element. For culturing in microplates, 10000 cells per well
were seeded in 384-well, black-wall, clear bottom assay plates with low fluorescence
background (Corning), and cultured in Dulbecco’s modified eagle medium
(Invitrogen,10569-010)supplementedwith10%dialyzedfetalbovineserum,0.1 mM
non-essential amino acids, 25 mM Hepes (pH 7.3), 100 U/ml penicillin, and
100 mg/ml streptomycin. After overnight culture, the cells were stimulated with
ligands for 5 hrs in a humidified 37uC/5% CO2, and then loaded with the cell
permeable LiveBLAzer
TM FRET B/G substrate. After the two hour incubation the
coumarin to fluorescein ratio was measured using Tecan Safire II microplate reader
(Ma ¨nnedorf, Switzerland). The activation of GPR35 by agonists leads to the
recruitment of b-arrestin/TEV protease fusion proteins to the activated GPR35. As a
result, the protease cleaves the Gal4-VP16 transcription factor from the receptor,
which then translocates to the nucleus and activates the expression of b-lactamase.
The GPR35 activation increases the coumarin to fluorescein FRET (fluorescence
resonance energy transfer) ratio, which was used as a normalized reporter response.
ERKMAPKassays.Thep44/42MAPkinaseswereexaminedusingWesternblotting.
Whole cell lysates were collected after the cells were treated with a compound or
DMSO for 1 hr. Equivalent gel loading was confirmed by probing with anti-actin
body. The total ERK1/2 and phosphorylated ERK1/2 were blotted using respective
antibodies.
Receptor internalization assays. HT-29cells wereplated on an8-well chamber slide
(Nalge Nunc International, Rochester, NY, USA) with a seeding density of 10,000
cells per well and incubated at 37uC for 24 hrs. Next day, cells were stimulated with a
compound or equal amount of DMSO at 37uC for 1 hr. Afterwards, cells were fixed
with 4% formaldehyde in 1 x PBS for 15 min, followed by blocking and
permeabilization in a buffer containing 4% goat serum, 0.1 % bovine serum albumin
(BSA), 0.1% Triton X100 in 1 x PBS for 2 hrs. After 5 min wash with PBS, fixed cells
were incubated with the anti-GPR35 (1:500) (anti-GPR35, T-14, intracellular
domain)(SantaCruzbiotechnology,SantaCruz,CA,USA)in3%BSA/PBSbufferfor
24 hrs, followed by incubation with secondary antibody Alexa FluorH 594 donkey
anti-goat IgG (H1L) (1:500) (Invitrogen) in 3% BSA/PBS for 1 hr at room
temperature. Cells were finally washed once with PBS and sealed with 1.5 mm thick
glass cover-slip (Corning, NY). Dried slides were stored at 4uC until imaging.
Confocal imaging was performed with Zeiss confocal microscope Axiovert 40. The
specificity of anti-GPR35 was confirmed by the control peptide from the supplier.
Staining showed that the control peptide completely blocked the staining of HT-29
cells with the anti-GPR35 antibody. The collected images were analyzed using
MacBiophotonics Image J software (http://www.macbiophotonics.ca/
downloads.htm).
1. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are
there? Nat. Rev. Drug Discov. 5, 993–996 (2006).
2. Strachan, R. T., Ferrara, G. & Roth, B. L. Screening the receptorome: an efficient
approach for drug discovery and target validation. Drug Discov. Today 11,7 0 8 –
716 (2006).
3. Wise, A., Jupe, S. C. & Rees, S. The identification of ligands at orphan G-protein
coupled receptors. Ann. Rev. Pharmacol. Toxicol. 44, 43–66 (2004).
4. O’Dowd, B. F. et al. Discovery of three novel G-protein-coupled receptor genes.
Genomics 47, 310–313 (1998).
5. Okumura, S. etal.Cloning ofa G-protein-coupled receptorthat shows anactivity
to transform NIH3T3 cells and is expressed in gastric cancer cells. Cancer Sci. 95,
131–135 (2004).
6. MacKenzie, A. E., Lappin, J. E., Taylor, D. L., Nicklin, S. A. & Milligan, G. GPR35
as a novel therapeutic target. Front. Endocrin. 2, e68 (2011).
7. Yang, Y. et al. G-protein-coupled receptor 35 is a target of the asthma drugs
cromolyn disodium and nedocromil sodium. Pharmacology 86, 1–5 (2010).
8. parfel, L. et al. Transcriptional signature of human macrophages exposed to the
environmental contaminant benzo(a)pyrene. Toxicol. Sci. 114, 247–259 (2010).
9. Min, K. D. et al. Identification of genes related to heart failure using global gene
expression profiling of human failing myocardium. Biochem. Biophys. Res.
Commun. 393, 55–60 (2010).
10. Shrimpton, A. E., Braddock, B. R., Thomson, L. L., Stein, C. K. & Hoo, J. J.
Molecular delineation of deletions on 2q37.3 in three cases with an Albright
hereditary osteodystrophy-like phenotype. Clin. Genet. 66, 537–544 (2004).
11. Wang, J. et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor
GPR35. J. Biol. Chem. 281, 22021–22028 (2006).
12. Oka, S., Ota, R., Shima, M., Yamashita, A. & Sugiura, T. GPR35 is a novel
lysophosphatidic acid receptor. Biochem. Biophys. Res. Comm. 395, 232–237
(2010).
13.Chun,J.,Hla,T.,Lynch,K.R.,Spiegel,S.&Moolenaar,W.H.InternationalUnion
of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor
nomenclature. Pharmacol. Rev. 62, 579–587 (2010).
14. Deng, H., Hu, H. & Fang, Y. Tyrphostin analogs are GPR35 agonists. FEBS Lett.
585, 1957–1962 (2011).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 373 | DOI: 10.1038/srep00373 1115.Kvetnansky,R.,Sabban,E.L.&Palkovits,M.Catecholaminergicsystemsinstress:
structural and molecular genetic approaches. Physiol. Rev. 89, 535–606 (2009).
16. Cheng, S. Y., Leonard, J. L. & Davis, P. J. Molecular aspects of thyroid hormone
actions. Endocr. Rev. 31, 139–170 (2010).
17. Deng, H. et al. Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and
thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled
receptor-35 (GPR35) agonists. J. Med. Chem. 54, 7385–7396 (2011).
18. Fang, Y., Ferrie, A. M., Fontaine, N. H., Mauro, J. & Balakrishnan, J. Resonant
waveguide grating biosensor for living cell sensing. Biophys. J. 91, 1925–1940
(2006).
19. Fang, Y. The development of label-free cellular assays for drug discovery. Expert
Opin. Drug Discov. 6, 1285–1298 (2011).
20. Fang, Y. Non-invasive optical biosensor for probing cell signaling. Sensors 7,
2316–2329 (2007).
21. Kenakin, T. Cellular assays as portals to seven-transmembrane receptor-based
drug discovery. Nat. Rev. Drug Discov. 8, 617–626 (2009).
22. Taniguchia, Y., Tonai-Kachi, H. & Shinjo, K. Zaprinast, a well-known cyclic
guanosinemonophosphate-specificphosphodiesteraseinhibitor,isanagonistfor
GPR35. FEBS Lett. 580, 5003–5008 (2006).
23. Zhao, P. et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent
activatorof ERKand b-arrestin 2, with antino-ciceptiveactivity. Mol.Pharmacol.
78, 560–568 (2010).
24.Jenkins,L.etal.Identificationofnovelspecies-selectiveagonistsoftheG-protein-
coupled receptor GPR35 that promote recruitment of b-arrestin-2 and activate
Ga13. Biochem. J. 432, 451-459 (2010).
25. Tyrosine metabolism pathway, KEGG database. http://www.genome.jp/kegg/
pathway/map/map00350.html.
26.Slominski,A.,Tobin,D.J.,Shibahara,S.&Wortsman,J.Melaninpigmentationin
mammalian skin and its hormonal regulation. Physiol. Rev. 84,155–1228 (2004).
27. Flamant, F. et al. International Union of Pharmacology. LIX. The pharmacology
andclassificationofthenuclearreceptorsuperfamily:thyroidhormonereceptors.
Pharmacol. Rev. 58, 705–711 (2006).
28.Pacher,P.,Beckman,J.S.&Liaudet,L.Nitricoxideandperoxynitriteinhealthand
disease. Physiol. Rev. 87, 315–324 (2007).
29. Levitzki, A. & Mishani, E. Tyrphostins and other tyrosine kinase inhibitors. Ann.
Rev. Biochem. 75, 93–109 (2006).
30.Lopez,V.M.,Decatur,C.L.,Stamer,W.D.,Lynch,R.M.&McKay,B.S.L-DOPA
is an endogenous ligand for OA1. PLoS Biol. 306, e236 (2008).
31. He, W. et al. Citric acid cycle intermediates as ligands for orphan G-protein-
coupled receptors. Nature 429, 188–193 (2004).
32. Bergh, J. J. et al. Integrin aVb3 contains a cell surface receptor site for thyroid
hormone that is linked to activation of mitogen-activated protein kinase and
induction of angiogenesis. Endocrinology 146, 2864–2871 (2005).
33.Fang,Y.&Ferrie,A.M.Label-freeopticalbiosensorforligand-directedfunctional
selectivity acting on b2 adrenoceptor in living cells. FEBS Lett. 582, 558–564
(2008).
34. Hara, H., Walsh, N., Yamada, K. & Jimbow, K. High plasma level of a eumelanin
precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker
for malignant melanoma. J. Invest. Dermatol. 102, 501–505 (1994).
35. Slominski, A., Zmijewski, M. A. & Pawelek, J. L-tyrosine and L-
dihydroxyphenylalanine as hormone-like regulators of melanocyte functions.
Pigment Cell Melanoma Res. 25, 14–27 (2012).
36. Slominski, A. & Pruski, D. L-dopa binding sites in rodent melanoma cells.
Biochim. Biophys. Acta 1139, 324–328 (1992).
37. Arias-Barrau, E. et al. The homogentisate pathway: a central catabolic pathway
involved in the degradation of L-phenylalanine, L-tyrosine, and 3-
hydroxyphenylacetate in Pseudomonas putida. J. Bacteriol. 186, 5062–5077
(2004).
38.Haynes,D.R.,Wright,P.F.,Gadd,S.J.,Whitehouse,M.W.&Vernon-Roberts,B.
Is aspirin a prodrug for antioxidant and cytokine-modulating oxymetabolites?
Agents Actions 39, 49–58 (1993).
39. Ziu, M. M. & Giasuddin, A. S. M. Plasma levels of aspirin metabolites in Libyan
patientswithrheumatoidarthritisandrheumaticfever.J.IslamicAcad.Sci.6,36–
41 (1993).
40. Petersen, M. et al. Evolution of rosmarinic acid biosynthesis. Phytochemistry 70,
1663–1679 (2009).
41. Zhou, L., Zuo, Z. & Chow, M. S. S. Danshen: an overview of its chemistry,
pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 45, 1345–
1359 (2005).
42.Yang,Y.,Fu,A.,Wu,X.&Reagan,J.D.GPR35isatargetoftheloopdiureticdrugs
bumetanide and furosemide. Pharmacology 89, 13–17 (2012).
43. Economidou, F., Douka, E., Tzanela, M., Nanas, S. & Kotanidou, A. Thyroid
function during critical illness. Hormones 10, 117–124 (2011).
44. Peeters, R. P. et al. Tissue thyroid hormone levels in critical illness. J. Clin.
Endocrinol. Metab. 90, 6498–6507 (2005).
45. Stathatos, N. & Daniels, G. H. Autoimmune thyroid disease. Curr. Opin.
Rheumatol. 24, 70–75 (2012).
46. Wu, S. Y., Green, W. L., Huang, W. S., Hays, M. T. & Chopra, I. J. Alternate
pathways of thyroid hormone metabolism. Thyroid 15, 943–958 (2005).
47.Klein,I.&Ojamaa,K.Thyroidhormoneandthecardiovascularsystem.N.Engl.J.
Med. 344, 501–509 (2001).
48. Eisenhofer, G., Kopin, I. J. & Goldstein, D. S. Catecholamine metabolism: A
contemporary view with implications for physiology and medicine. Pharmacol.
Rev. 56, 331–349 (2004).
49.Scheinin,M.&Karhuvaara,S.Plasma3,4-dihydroxyphenylglycol(DHPG)and3-
methoxy-4-hydroxyphenylglcol (MHPG) are insensitive to indicators of a2-
adrenoceptor mediated regulation of norepinephrine release in healthy human
volunteers. Life Sci. 49, 75–84 (1991).
50. Nemirovskiy, O. V. et al. Plasma 3-nitrotyrosine is a biomarker in animal models
of arthritis: Pharmacological dissection of iNOS’ role in disease. Nitric Oxide 20,
150–156 (2009).
51. Frost, M. T., Halliwell, B. & Moore, K. P. Analysis of free and protein-bound
nitrotyrosine in human plasma by a gas chromatography/mass spectrometry
method that avoids nitration artifacts. Biochem. J. 345, 453–458(2000).
52. Inoue, H., Hisamatsu, K., Ando, K., Ajisaka, R. & Kumagai, N. Determination of
nitrotyrosine and related compounds in biological specimens by competitive
enzyme immunoassay. Nitric Oxide 7, 11–17(2002).
53. Greenacre, S. A. & Ischiropoulos, H. Tyrosine nitration: localisation,
quantification, consequences for protein function and signal transduction. Free
Radic. Res. 34, 541–581(2001).
54. Fukuyama, N. et al. Clinical evidence of peroxynitrite formation in chronic renal
failure patients with septic shock. Free Radic. Biol. Med. 22, 771–774 (1997).
Author contributions
H. Deng designed and performed DMR and Tango assays, and analyzed the data. H. Hu
conductedERKphosphorylationandreceptorinternalizationassays,andanalyzedthedata.
Y. Fang conceived the idea, designed experiments, analyzed all data, and wrote the
manuscript.
Additional information
Competing financial interests: Y.F., H.D., and H.H. are employee and stock holders of
Corning Incorporated.
License: This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
How to cite this article: Deng, H., Hu, H. & Fang, Y. Multiple tyrosine metabolites are
GPR35 agonists. Sci. Rep. 2, 373; DOI:10.1038/srep00373 (2012).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 373 | DOI: 10.1038/srep00373 12